Head-to-Head Trials

Novo’s CagriSema Falls Short of Lilly’s Tirzepatide in 84-Week Head‑to‑Head Trial

The setback reinforces Lilly’s advantage — Novo now targets higher doses with an FDA decision expected late 2026.